40 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
12 Mar 24
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
4:06pm
& CEO of Aligos Therapeutics. “In addition, we presented unprecedented antiviral activity from our ALG-000184 program for chronic hepatitis B (CHB … such as chronic hepatitis B (CHB) and coronaviruses.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning
SC TO-I
EX-99
ALGS
Aligos Therapeutics Inc
30 Jan 24
Issuer tender offer statement
7:04am
), coronavirus (e.g., SARS-CoV-2 and related infections) and chronic hepatitis B (CHB). We utilize our proprietary small molecule and oligonucleotide
424B3
ALGS
Aligos Therapeutics Inc
28 Nov 23
Prospectus supplement
4:01pm
steatohepatitis (NASH), coronavirus (e.g., SARS-CoV-2 and related infections) and chronic hepatitis B (CHB). We utilize our proprietary small molecule
8-K
EX-99.1
xw0t50
2 Nov 23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
ipbdbkf
3 Aug 23
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
o1cv8r4eg vwrro52
4 May 23
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
4:05pm
CORRESP
73b1r
22 Dec 22
Correspondence with SEC
12:00am
8-K
EX-99.1
2ssjpp
2 Nov 22
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
zx9d4jus6a9f8c2
4 Aug 22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
b4mi44f4ixyoh1ud0
4 May 22
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
4:06pm
8-K
uvb96
22 Mar 22
Other Events
8:23am